N
Niklas Hammar
Researcher at Karolinska Institutet
Publications - 262
Citations - 12674
Niklas Hammar is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Population & Diabetes mellitus. The author has an hindex of 55, co-authored 248 publications receiving 10865 citations. Previous affiliations of Niklas Hammar include Stockholm Centre of Public Health & AstraZeneca.
Papers
More filters
Journal ArticleDOI
The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months
Björn Wettermark,Björn Wettermark,Niklas Hammar,Niklas Hammar,C. MichaelFored,Andrejs Leimanis,Petra Otterblad Olausson,Ulf Bergman,Ingemar Persson,Ingemar Persson,Anders Sundström,Barbro Westerholm,Måns Rosén +12 more
TL;DR: The content and potentials of the new Swedish national register on prescribed and dispensed medicines are described.
Journal ArticleDOI
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod,Matthew A. Cavender,Alex Z. Fu,John P.H. Wilding,Kamlesh Khunti,Reinhard W. Holl,Anna Norhammar,Kåre I. Birkeland,Kåre I. Birkeland,Marit E. Jørgensen,Marcus Thuresson,Niki Arya,Johan Bodegard,Niklas Hammar,Niklas Hammar,Peter Fenici +15 more
TL;DR: Treatment with SGLT-2i versus other glucose-lowering drugs was associated with a lower risk of HHF and death, suggesting that the benefits seen with empagliflozin in a randomized trial may be a class effect applicable to a broad population of patients with type 2 diabetes mellitus in real-world practice.
Journal ArticleDOI
Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation.
TL;DR: Ischaemic stroke is about as common in PxAF as in PermAF, and about twice as common as in the general population, and it is therefore important to increase the use of anticoagulants among P xAF patients in accordance with current guideline recommendations.
Journal ArticleDOI
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study
Mikhail Kosiborod,Carolyn S.P. Lam,Shun Kohsaka,Dae Jung Kim,Dae Jung Kim,Avraham Karasik,Jonathan E. Shaw,Navdeep Tangri,Su-Yen Goh,Marcus Thuresson,Hungta Chen,Filip Surmont,Niklas Hammar,Niklas Hammar,Peter Fenici +14 more
TL;DR: In this article, a randomized trial demonstrated a lower risk of cardiovascular events with SGLT-2 inhibitors in patients with type 2 diabetes (T2D) at high risk of adverse events.
Journal ArticleDOI
High effort, low reward, and cardiovascular risk factors in employed Swedish men and women: baseline results from the WOLF Study.
Richard Peter,Lars Alfredsson,Niklas Hammar,Johannes Siegrist,Töres Theorell,Peter Westerholm +5 more
TL;DR: Findings lend support to the hypothesis that effort-reward imbalance represents a specific constellation of stressful experience at work related to cardiovascular risk.